InvestorsHub Logo
Followers 466
Posts 26939
Boards Moderated 2
Alias Born 09/11/2006

Re: None

Wednesday, 10/17/2007 7:11:00 PM

Wednesday, October 17, 2007 7:11:00 PM

Post# of 1467
2) Javelin Pharma (JAV): Imminent approval for Dyloject in UK expected with planned 4Q07 launch plus 2 additional pipeline candidates with low clinical risk. Focus on pain management via unique delivery mechanisms for existing, approved drugs such as diclofenac (eg Dyloject) with estimated sales potential over $500 million for all 3 of Javelin's drug candidates.

http://seekingalpha.com/article/49796-top-10-emerging-biotech-stocks?source=yahoo


surf's up......crikey